126 related articles for article (PubMed ID: 28730155)
1. Surveillance Study of Influenza Occurrence and Immunity in a Wisconsin Cohort During the 2009 Pandemic.
Lo CY; Strobl SL; Dunham K; Wang W; Stewart L; Misplon JA; Garcia M; Gao J; Ozawa T; Price GE; Navidad J; Gradus S; Bhattacharyya S; Viboud C; Eichelberger MC; Weiss CD; Gorski J; Epstein SL
Open Forum Infect Dis; 2017; 4(2):ofx023. PubMed ID: 28730155
[TBL] [Abstract][Full Text] [Related]
2. Cross-Reactive Neuraminidase-Inhibiting Antibodies Elicited by Immunization with Recombinant Neuraminidase Proteins of H5N1 and Pandemic H1N1 Influenza A Viruses.
Liu WC; Lin CY; Tsou YT; Jan JT; Wu SC
J Virol; 2015 Jul; 89(14):7224-34. PubMed ID: 25948745
[TBL] [Abstract][Full Text] [Related]
3. Synthetic Toll-like receptor 4 (TLR4) and TLR7 ligands as influenza virus vaccine adjuvants induce rapid, sustained, and broadly protective responses.
Goff PH; Hayashi T; Martínez-Gil L; Corr M; Crain B; Yao S; Cottam HB; Chan M; Ramos I; Eggink D; Heshmati M; Krammer F; Messer K; Pu M; Fernandez-Sesma A; Palese P; Carson DA
J Virol; 2015 Mar; 89(6):3221-35. PubMed ID: 25568203
[TBL] [Abstract][Full Text] [Related]
4. Vaccination with Recombinant Parainfluenza Virus 5 Expressing Neuraminidase Protects against Homologous and Heterologous Influenza Virus Challenge.
Mooney AJ; Gabbard JD; Li Z; Dlugolenski DA; Johnson SK; Tripp RA; He B; Tompkins SM
J Virol; 2017 Dec; 91(23):. PubMed ID: 28931689
[TBL] [Abstract][Full Text] [Related]
5. A Bivalent Heterologous DNA Virus-Like-Particle Prime-Boost Vaccine Elicits Broad Protection against both Group 1 and 2 Influenza A Viruses.
Jiang W; Wang S; Chen H; Ren H; Huang X; Wang G; Chen Z; Chen L; Chen Z; Zhou P
J Virol; 2017 May; 91(9):. PubMed ID: 28179535
[TBL] [Abstract][Full Text] [Related]
6. Universal H1N1 influenza vaccine development: identification of consensus class II hemagglutinin and neuraminidase epitopes derived from strains circulating between 1980 and 2011.
Moise L; Terry F; Ardito M; Tassone R; Latimer H; Boyle C; Martin WD; De Groot AS
Hum Vaccin Immunother; 2013 Jul; 9(7):1598-607. PubMed ID: 23846304
[TBL] [Abstract][Full Text] [Related]
7. Unmasking Stem-Specific Neutralizing Epitopes by Abolishing N-Linked Glycosylation Sites of Influenza Virus Hemagglutinin Proteins for Vaccine Design.
Liu WC; Jan JT; Huang YJ; Chen TH; Wu SC
J Virol; 2016 Oct; 90(19):8496-508. PubMed ID: 27440889
[TBL] [Abstract][Full Text] [Related]
8. Neuraminidase-Inhibiting Antibody Titers Correlate with Protection from Heterologous Influenza Virus Strains of the Same Neuraminidase Subtype.
Walz L; Kays SK; Zimmer G; von Messling V
J Virol; 2018 Sep; 92(17):. PubMed ID: 29925654
[TBL] [Abstract][Full Text] [Related]
9. Sequential Immunization With Live-Attenuated Chimeric Hemagglutinin-Based Vaccines Confers Heterosubtypic Immunity Against Influenza A Viruses in a Preclinical Ferret Model.
Liu WC; Nachbagauer R; Stadlbauer D; Solórzano A; Berlanda-Scorza F; García-Sastre A; Palese P; Krammer F; Albrecht RA
Front Immunol; 2019; 10():756. PubMed ID: 31105689
[TBL] [Abstract][Full Text] [Related]
10. Influenza viruses and cross-reactivity in healthy adults: humoral and cellular immunity induced by seasonal 2007/2008 influenza vaccination against vaccine antigens and 2009 A(H1N1) pandemic influenza virus.
Iorio AM; Bistoni O; Galdiero M; Lepri E; Camilloni B; Russano AM; Neri M; Basileo M; Spinozzi F
Vaccine; 2012 Feb; 30(9):1617-23. PubMed ID: 22245606
[TBL] [Abstract][Full Text] [Related]
11. Progress on adenovirus-vectored universal influenza vaccines.
Xiang K; Ying G; Yan Z; Shanshan Y; Lei Z; Hongjun L; Maosheng S
Hum Vaccin Immunother; 2015; 11(5):1209-22. PubMed ID: 25876176
[TBL] [Abstract][Full Text] [Related]
12. Seasonal influenza vaccination is the strongest correlate of cross-reactive antibody responses in migratory bird handlers.
Oshansky CM; Wong SS; Jeevan T; Smallwood HS; Webby RJ; Shafir SC; Thomas PG
mBio; 2014 Dec; 5(6):e02107. PubMed ID: 25491354
[TBL] [Abstract][Full Text] [Related]
13. Complement C3 Plays a Key Role in Inducing Humoral and Cellular Immune Responses to Influenza Virus Strain-Specific Hemagglutinin-Based or Cross-Protective M2 Extracellular Domain-Based Vaccination.
Kim YJ; Kim KH; Ko EJ; Kim MC; Lee YN; Jung YJ; Lee YT; Kwon YM; Song JM; Kang SM
J Virol; 2018 Oct; 92(20):. PubMed ID: 30068650
[TBL] [Abstract][Full Text] [Related]
14. Vaccination with Vesicular Stomatitis Virus-Vectored Chimeric Hemagglutinins Protects Mice against Divergent Influenza Virus Challenge Strains.
Ryder AB; Nachbagauer R; Buonocore L; Palese P; Krammer F; Rose JK
J Virol; 2015 Dec; 90(5):2544-50. PubMed ID: 26676789
[TBL] [Abstract][Full Text] [Related]
15. Hemagglutinin-specific CD4
Tan S; Zhang S; Wu B; Zhao Y; Zhang W; Han M; Wu Y; Shi G; Liu Y; Yan J; Wu G; Wang H; Gao GF; Zhu F; Liu WJ
Vaccine; 2017 Oct; 35(42):5644-5652. PubMed ID: 28917539
[TBL] [Abstract][Full Text] [Related]
16. Protection against H5N1 Influenza Virus Induced by Matrix-M Adjuvanted Seasonal Virosomal Vaccine in Mice Requires Both Antibodies and T Cells.
Cox F; Baart M; Huizingh J; Tolboom J; Dekking L; Goudsmit J; Saeland E; Radošević K
PLoS One; 2015; 10(12):e0145243. PubMed ID: 26696245
[TBL] [Abstract][Full Text] [Related]
17. Increased Protein Degradation Improves Influenza Virus Nucleoprotein-Specific CD8+ T Cell Activation In Vitro but Not in C57BL/6 Mice.
Altenburg AF; van de Sandt CE; van Trierum SE; De Gruyter HLM; van Run PRWA; Fouchier RAM; Roose K; Saelens X; Volz A; Sutter G; de Vries RD; Rimmelzwaan GF
J Virol; 2016 Nov; 90(22):10209-10219. PubMed ID: 27581985
[TBL] [Abstract][Full Text] [Related]
18. Heterosubtypic Protections against Human-Infecting Avian Influenza Viruses Correlate to Biased Cross-T-Cell Responses.
Zhao M; Liu K; Luo J; Tan S; Quan C; Zhang S; Chai Y; Qi J; Li Y; Bi Y; Xiao H; Wong G; Zhou J; Jiang T; Liu W; Yu H; Yan J; Liu Y; Shu Y; Wu G; Wu A; Gao GF; Liu WJ
mBio; 2018 Aug; 9(4):. PubMed ID: 30087171
[TBL] [Abstract][Full Text] [Related]
19. Serum strain-specific or cross-reactive neuraminidase inhibiting antibodies against pandemic А/California/07/2009(H1N1) influenza in healthy volunteers.
Desheva YA; Smolonogina TA; Donina SA; Rudenko LG
BMC Res Notes; 2015 Apr; 8():136. PubMed ID: 25889924
[TBL] [Abstract][Full Text] [Related]
20. Co-administration of certain DNA vaccine combinations expressing different H5N1 influenza virus antigens can be beneficial or detrimental to immune protection.
Patel A; Gray M; Li Y; Kobasa D; Yao X; Kobinger GP
Vaccine; 2012 Jan; 30(3):626-36. PubMed ID: 22119588
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
